Last reviewed · How we verify
NCT06679998: AAPB
A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection
Phase 1 trial testing Single dose, AAPB by injection, intravenous drip. in Acute Ischemic Stroke (AIS) in 56 participants. Not yet recruiting.
12 January 2026
Quick facts
| Lead sponsor | Jiangsu Kanion Pharmaceutical Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 56 |
| Start date | 14 November 2024 |
| Primary completion | 12 January 2026 |
| Estimated completion | 26 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Single dose, AAPB by injection, intravenous drip. — full drug profile →
- Single dose, placebo, intravenous drip.
- Multiple dosing, AAPB for injection, intravenous drip — full drug profile →
- Multiple dosing, placebo, IV drip
Conditions studied
- Acute Ischemic Stroke (AIS) — all drugs for Acute Ischemic Stroke (AIS) →
Sponsor
Jiangsu Kanion Pharmaceutical Co., Ltd — full company profile →
Who can join
Adults 18 to 45, any sex, with Acute Ischemic Stroke (AIS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase I clinical to evaluate the safety and tolerability of single and multiple intravenous infusions of AAPB at different doses over 7 consecutive days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06679998
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Ischemic Stroke (AIS)
Currently open trials in the same condition.
- NCT06210633 — Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke · recruiting
Other Jiangsu Kanion Pharmaceutical Co., Ltd trials
Trials by the same sponsor.
- NCT07126171 — A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever · NA · not yet recruiting
- NCT05192304 — Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia · Phase 1 · unknown
- NCT07200362 — Study of Compound Nanxing Zhitong Ointment in the Treatment of Chronic Pain in Musculoskeletal System · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06679998 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Kanion Pharmaceutical Co., Ltd
- Last refreshed: 8 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06679998.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing